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Considering the inadequacies of current therapeutic regimens for
infantile spasms (IS), and the frequent and serious side effects of
Some regimens, the ongoing search for more enhanced protocols is
understandable.
Materials and Methods:
We have compared the therapeutic and adverse effects of vitamin
B6 given in high doses with those of prednisolone in a randomized
controlled clinical trial. Vitamin B6 (40mg/kg/24hr) and prednisolone
(1.5mg/kg/day) were given to in 22 and 15 patients respectively, and
the patients were followed for at least 6 months.
Results:
Response to treatment was slightly better in the prednisolone group
but the difference was not significant (p=0.4). On the other hand
adverse effects were also seen more frequently with prednisolone.
Conclusion:
We conclude that high dose vitamin B6 should be considered as an
alternative method of treatment; it seems that it can be safely used
where there is contraindication to use other antiepileptic drugs or
where they have failed; even in newly diagnosed cases of IS.
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Infantile spasms (IS), one of the most serious epileptic syndromes of infancy,
responds poorly to most conventional treatments, with the outcome being frequently
unfavorable in terms of seizure control and cognitive development (1-5).
Many antiepileptic drugs have been tried (2). The indisputable role of corticosteroids
in treatment of IS has been recognized many years; in fact, since Sorel (6) reported
the first favourable response with the use of ACTH in 1958, steroids in the form
of natural ACTH, synthetic ACTH, tetracosactide, prednisolone, and hydrocortisone
have remained the first line of treatment for IS. Nevertheless, frequent and serious
side effects of steroids have always urged researchers to look for less hazardous
therapeutic methods (7-9). Beside steroids which are still considered as the
cornerstone of the treatment, nitrazepam, vigabatrin, sodium valproate, vitamin
B6, and zonisamide are among the alternatives; felbamate, lamotrigine, and
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Topiramate, used as second line therapeutic agents (10-
13); unfortunately however, most of the other
aforementioned antiepileptics also have well known
adverse effects which restrict their safe use (1,2,14,15).
Among the more recently recommended therapeutic
regimens, high dose vitamin B6 is one of the most popular
(16,17). Vitamin B6 (pyridoxine) exerts its antiepileptic
effect by increasing the concentration of GABA in the
CNS. Pyridoxal phosphate, the active metabolite of
vitamin B6, is the coenzyme for glutamate decarboxylase
and GABA transaminase, the enzymes necessary for the
production and metabolism of the central nervous system
GABA (18, 19).
In the present study we have tried to evaluate vitamin
B6 as a treatment for IS in comparison to prednisolone,
the generally accepted standard therapy for the condition.
Patients and Methods
Our study was a randomized, clinical trial in which we
used a variety of techniques and modalities including
interview, history taking, physical exam, and data
processing software.
All of the patients presenting to our center between
August 2002 and Aug 2003 with syndrome of infantile
spasms (IS), were enrolled, their past medical history, in
particular their perinatal history, was reviewed and a
thorough physical and neurological exam was performed.
Weight, head circumference, and vital signs were recorded.
The patients’ age, duration of symptoms, sex, and
frequency of seizures were recorded in specifically
designed questionnaires, as were any other unusual
observations.
Biochemical studies including serum electrolytes, blood
sugar, and liver function tests were performed, as were
other metabolic and serologic investigations, including,
blood gas, amino acids and TORCH studies, to uncover
the underlying disorder. In addition to the above, brain
CT scan and EEG were obtained; the EEG was analyzed
for abnormal patterns, although having hypsarrhytmia
was not a prerequisite for subject enrollment in this study.
After completing the above investigations, treatment was
started by either vitamin B6 or prednisolone. Each patient
was randomly placed in either the “test” (treated by
vitamin B6) or the “control” (treated by prednisolone)
group. Vitamin B6 was given at a dose of 40mg/kg/24hr,
and prednisolone at.1.5mg/kg/24hr, each being divided
into 3 doses/day for at least two weeks. At the end of
this period, subjects were assessed for decrease in seizure
frequency, improvement in alertness, and developmental
scale. The criteria of “response to treatment” were: 1.
Interruption of seizures or a decrease of over 50% in
their frequency, and 2. Improvement in the neurological
exam, including alertness and developmental status.
The patients were closely observed for appearance of
drug side effects; to this end, blood pressure was checked
and urine was tested for glucose daily; blood was drawn
for electrolytes every 3 days; patients were weighed at
the end of the 1st and 2nd weeks of therapy; they were
also observed for any clues to infections. Patients were
evaluated for therapeutic response after 2 weeks and
were followed after discharge by outpatient visits on a
monthly basis at least for 6 months.
For one year 38 patients were studied, at the end of which
8 patients were excluded, 7 owing to insufficient follow-
up, and 1 due to suspicious investigations and doubtful
diagnosis. Of the 30 patients remaining in the study
group, 15 received vitamin B6, 8 were given prednisolone,
and the other 7 patients received both drugs at different
times; in fact these last seven patients were assessed
twice, as they participated both once in the “test” and
again in the “control” groups. As a result, vitamin B6
was totally tested in 22 and prednisolone in 15 patients.
Although not many ethical considerations called for
attention in this study, nevertheless, some were taken
into account.All of the potential adverse effects were
explained to the parents before the onset of the treatment
and informed consent was obtained. Also all information
concerning the patients was kept secret.
Results
The study group comprised 37 patients (age range 1.5 to
24 months), with nearly half of them, (18) aged between
6 and 12 months. The patients were predominantly male
(26 out of 37(70.3%) and 11 patients (29.7%) were
female. “Flexion” type of IS was observed in 17(45.9%)
of patients, 8 had “extension” type (21.6%), and finally
12 patients had the “mixed” type.
Etiologically, a clear underlying cause was identified in
20 of the patients (symptomatic group). Of the remaining
17 patients, 7 had apparently normal neurological
development prior to onset of the seizures (idiopathic
group), and the other 10 patients reported developmental
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Table 1- Rate of seizure reduction after treatment
tdelay before appearance of the spasms (cryptogenic
group). Among the patients, with a specific known
etiology (symptomatic group), 6 had history of different
perinatal problems including: asphyxia, major infections,
hypoglycemia, or respiratory distress and acidosis. CNS
dysgenesis, tuberous sclerosis, and inborn errors of
metabolism, were each observed in 3 patients; and lastly
congenital rubella syndrome and postnatal herpes
encephalitis were each detected in one case.
Eighteen of the patients showed hypsarrhythmia in their
EEG, 15 had other nonspecific abnormal patterns specially
HVSW (high voltage slow waves); EEG did not reveal
significant findings in the other 4.
No significant difference existed between the “test” and
“control” groups in terms of age, sex, clinical form of
seizure (flexion, extension, or mixed type), etiology, and
EEG findings.
Patients who received prednisolone showed a more
pronounced decrease in seizure frequency, but the
difference not significant (p=0.4) (table1). A decrease
more than 50% in seizures was considered as the cut-off
point for response to treatment. Based on this, 66.7% of
the patients in the prednisolone group and 36.3% of the
patients in the vitamin B6 group showed therapeutic
response.
Difference was even more negligible in terms of
improvement in developmental status, and “Fischer” test
did not reveal any significant differences between the
two groups (table 2). A remarkable improvement was
detected in 13.7% of patients receiving vitamin B6 and
20% of patients in the prednisolone group; it needs to be
mentioned that one patient taking vitamin B6 recovered
completely, whereas not a single such case was seen in
the prednisolone group.
Of 7 cases who had received both drugs separately, 3
had no response to either of them; in three others vitamin
B6 failed, while prednisolone showed relative success;
in the last case vitamin B6 was successful, contrary to
results with prednisolone.The reason for starting the
second drug was lack of success with the first drug in 5
cases,and infections following prednisolone in the other
2. Regarding untoward effects, in particular the major
ones leading to discontinuation of the drug, these were
seen more commonly in the prednisolone group (infection
and hypertension in each in three patients, liver
dysfunction in two) (table 3).
Discussion
Seki and Takayamu(20) in 1996 tried a combination
therapy of high dose Pyridoxal phosphate and low dose
corticotropin for treatment of infantile spasms (IS) in an
attempt to reduce side effects of corticotherapy, and they
achieved favorable results.
Many authors -especially the Japanese- have tried vitamin
B6 with high doses as the mono-therapy for IS in recent
years (21-27); the reported range of success has been
relatively wide. Through a meta-analysis in 2000, Ito et
al reviewed the status of the treatments undertaken for
IS in Japanese institutions and observed that vitamin B6
was the preferred first line drug for treatment (28), in
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contrast to the US where ACTH is the drug most used by child neurologists (24). At most of the institutions, vitamin
B6 was started at a dosage of 10 to 50 mg/kg/day and then was increased by 10 mg/kg/day every 3 to 5 days up to a
dosage of 40-50mg/kg/day. Fourteen institutions prescribed fixed dosages. Altogether high-dose vitamin B6 therapy
resulted in complete cessation of the spasms in 13% to 29% of patients [28).
We used the fixed dosage (40mg/kg/day) schedule in our study and found our results were similar to those of Ito et
al’s success rate for seizure control. Although in our study prednisolone controlled the seizures better than vitamin
B6 did, but the difference was not statistically significant (table1).  The difference between the two drugs was even
narrower in terms of improving the developmental state of the patients, with the two agents having very similar effects
(table2).
Table 2- Rate of improvement in developmental state after treatment
Fischer test did not reveal significant difference between the two groups
Table 3- Frequency of side effects observed with treatment
Fisher test did not reveal significant difference between the two groups
After intravenous B6 administration, apnea, lethargy, pallor, decreased responsiveness, and hypotonia may occur and
persist for several hours (29, 30). These reactions have been also reported less frequently after intramuscular
administration (31), and the initial oral dose (32). Believed to result from a massive initial release of GABA (32),
these symptoms are usually mild but on rare occasions have necessitated intubation and assisted ventilation (33). Loss
of appetite, periods of restlessness and crying, vomiting, and apathy have been reported during therapy for infantile
spasms with high doses of vitamin B6 (17)
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We used the oral route of administration and, in two
cases only, encountered vomiting severe enough to need
attention (smaller, more frequent meals). There were
almost no other remarkable side effects seen in patients
receiving vitamin B6. The four patients who showed
weight gain with vitamin B6 administration, were
dehydrated and emaciated infants at presentation whose
general condition improved later following hydration
and they regained their normal weight, in contrast to the
patients in prednisolone group whose weight gain was
due to development of cushingoid features. The treatment
of infantile spasms seems to be far from ideal, considering
the significant side effects seen in present medical
therapeutics believed to be effective. Also, further blinded
randomized clinical trials are needed to assess the long-
term social and cognitive outcomes. At the same time,
considering the above therapeutic results and especially
the rare adverse reactions of high-dose vitamin B6, we
conclude that this is a treatment well worth trying; it
seems that high-dose vitamin B6 can safely be used
where there are contraindications to use other antiepileptic
drugs or where they have failed; this applies to their use
in freshly diagnosed IS cases as well.
References :
1. Baram TZ:Myoclonus and myoclonic seizures.In: Swaiman
   KF, Ashwal S, Pediatric Neurology, Mosby , pp. 668-672,
   3rd ed.,1999.
2. Menkes JH, Sankar R: Paroxysmal disorders. In: Menkes
     JH, Sarnat HB(eds), Child neurology ,Philadelphia:Lippincot
  Williams & Wilkins,pp.941-945, 6th ed.,2000.
3. Aicardi J: Epilepsy and other seizure disorders. In: Aicardi
    J,Diseases of the Nervous System in Childhood, London:
   Cambridge University Press, pp. 581-583,2nd ed.,1998.
4. Kurokowa P, et al:West syndrome and Lennox Gestaut
    syndrome: a survey of the natural history. Pediatrics  65:
    81-85,1980.
5. Riikonen RA:Long term follow up study of 214 children
     with syndrome of infantile spasms. Neuropediatrics 13: 14-
    23, 1982.
6. Sorel L, Dusaucy-Bauloye A:A propos de 21 cas
     d’hypsarythmide Gibbs:  Son traitement spectaculaire par
  l ’ACRH.Acta Neurol  Belg 8:130-141,  1958.
7. Glaze DG, et al:Prospective study of outcome of infants
    with infantile spasms treated during controlled studies of
   ACTH and prednisolone. J Pediatr  112: 389-396,1988.
8. Hrachovy RA, Frost JD, Glaze DG: High-dose long-duration
      versus low-dose short-duration corticotrophin therapy for
   infantile spasms. J Pediatr  124: 803-806,1994.
9.  Riikonen R, Donner MA: ACTH therapy in infantile spasms:
   side effects. Arch Dis Child   55: 664-672,1980.
10. Wong Michael: Infantile spasms. Pediatric Neurology  24:
     2, pp. 89-98,2001.
11. Dreifuss F, et al: Infantile Spasms: Comparative trial of
     nitrazepam and corticotrophin. Arch Neurol  43: 1107-
      1110,1986.
12. Prats JM:Infantile spasms treated with high doses of sodium
      valproate: initial response and follow up. Dev Med Child
      Neurol  33: 617-625, 1991.
13. Chiron C, et al: Therapeutic trial of vigabatrin in refractory
      infantile spasms. J Child Neurol 2[suppl]: S52-S59,1991.
14. Bachman DS: Use of valproic acid in treatment of infantile
      spasms. Arch Neurol  39: 49-52,1982.
15. Gross-Tsur V, et al: Visual impairment in children with
    epilepsy treated with vigabatrin. Ann Neurol  48: 60-
      64,2000.
16. Blennow G, Stark I: High dose vitamin B6 treatment in
   infantile spasms. Neuropediatr 17: 7-10,1986.
17. Pietz J, Benninger C, Schafer H, et al: Treatment of infantile
     spasms with high dosage vitamin B6. Epilepsia  34(4): 757-
     763,1993.
18. Wyllie E: The treatment of epilepsy , Philadelphia :Lippincot
   Williams & Wilkins, pp. 995-996, 3rd ed., 2001.
19. Kurleman G, Loscher W, Dominck HC, et al: Disappearance
    of neonatal seizures and low CSF GABA levels after
      treatment with vitamin B6. Epilepsy Res   1:152-154,1987.
20. Takuma Y, Seki T: Combination therapy of infantile spasms
   with high-dose pyridoxal phosphate and low-dose
   corticotrophin. J Child Neurol 11: 35-40,1996.
21. Watanabe K: Medical treatment of West syndrome in Japan.
      J Child Neurol 10: 143-147,1995.
22. Suzuki Y ,et al: Outcome of initial treatment with high
      dose vitamin B6, valproate, or clonazepam in West
   syndrome.No-To-Hottatsu  28: 398-402,1996.
23. Seki T: Treatment of West syndrome: present and future
   perspectives. No-To-Hottatsu 29:91-99,1997.
24. Bobele GB, Bodensteiner  IB: The treatment of infantile
     spasms by child neurologists. J Child Neural 9:432-
      435,1994.
25. Appleton RE: The treatment of infantile spasms by paediatric
    neurologists in UK and Ireland. Dev Med Child Neurol
    38:278-279,1996.
26. Yoshida R: High dose pyridoxal phosphate therapy for
       West syndrome: Clinical study of 59 patients with special
     attention to side effects. J Tokyo Womens Med Colt
       63:1156-   1184, 1993.
VITAMIN B6 & TREATMENT OF INFANTILE SPASMS: A COMPARISON WITH STANDARD STEROID THERAPY
27. Benninger JPC, Schaefer H, Sontheimer D, et al: Treatment
     of infantile spasms with high-dosage vitamin Be. Epilepsia
     34:757-763, 1993.
28. Ito M, Seki T, Takuma Y: Current therapy for West syndrome
      in Japan. J Child Neurol   15: 424-425,2000.
29. Haenggeli CA, Girardin E, Paunier L: Pyridoxine-dependent
   seizures, clinical therapeutic aspects. Eur J Pediatr
     150:452-454,1991.
30. Mikati MA, Trevathan E, Krishnamorthy KS, et
     al:Pyridoxine-dependent epilepsy: EEG investigations
   and long term follow-up. Electroencephalogr Clin
      Neurophisiol  78: 215-221, 1991.
31. Bankier A, Turner M, Hopkins IJ. Pyridoxine-dependent:
    a wider clinical spectrum. Arch Dis Child   58: 415-
     418,1983.
32. Kroll J: Pyridoxine for neonatal seizures: an unexpected
    danger. Dev Med Child Neurol  27: 369-372,1985.
33. Heeley A, Puch RJP, Clayton BE, et al: Pyridoxol
       metabolism in vitamin B6 responsive convulsions of early
      infancy. Arch Dis Child   53: 794-802,1978.
22 Iran J Child Neurology  June 2006
VITAMIN B6 & TREATMENT OF INFANTILE SPASMS: A COMPARISON WITH STANDARD STEROID THERAPY
